About Us
Welcome to SYNAPTIGEN Group – a pioneering force in clinical research and biotech consulting. We are driven by a singular mission: to bridge the gap between cutting-edge clinical innovation and patient-centric care, creating a future where life-changing therapies reach those who need them most.
Drew Harrison
- Founder and CEO of SYNAPTIGEN
At SYNAPTIGEN, we understand the challenges faced by startups and established players alike. Our bespoke, client-focused solutions span every stage of the drug development lifecycle – from early-phase clinical trial design to late-stage regulatory approval and market access strategies.
Our Expertise Includes:
Clinical Trial Consulting: Expertise in study design, protocol development, and regulatory navigation.
Data Analytics: Powered by our AI-driven kineti-SYN™, offering real-time data monitoring, advanced analytics, and visual storytelling to empower decision-making.
Regulatory and Market Strategies: Seamlessly guiding you from IND submissions to post-market strategies, ensuring compliance and efficiency.
Patient-Centric Development: Advocating for patient voices in clinical research, designing decentralized and adaptive trials that prioritize accessibility and inclusivity.
Every solution we deliver is infused with a commitment to integrity, transparency, and collaboration. Our team works as an extension of yours, fostering partnerships that build trust and drive success.
Our Founder Drew Harrison, Founder and CEO, brings a wealth of experience and a unique perspective on harmonizing technology and human empathy in clinical research. Drew’s passion for patient advocacy drives SYNAPTIGEN’s approach to innovation and excellence.